Immune to Cancer: The CRI Blog
-
CRI Awards $29.3 Million to Fund Immunotherapies for All Kinds of Cancer
CRI committed new funds to accelerate research and clinical development.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
-
A Cross-Country Biking Trip to Raise Awareness and Funding for Cancer Immunotherapy Research
In memory of his lifelong friend, Bryce, Nolan and his wife, Ileana, decided to bike across country…
-
Ready. Raise. Rise. For CRI
Raise a flag in honor of someone affected by cancer and help us win a $75,000 donation.
-
New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…
-
When Is a Spot Not a Spot?
A ten-year effort to optimize a ubiquitous laboratory assay finally pays off.
-
Giving 100% to ‘100 in 100’ – YOU DID IT!
A big thank you to all of our supporters who made $100K in 100 Days a success!
-
Immunotherapy: 5 Ways to Stop Cancer
The Cancer Research Institute has created a series of short, animated videos that explain the basics of…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.